Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:41 PM
Ignite Modification Date:
2025-12-24 @ 10:41 PM
NCT ID:
NCT04552535
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of squamous or mixed histology non-small cell lung cancer
* Treated with pembrolizumab in combination with platinum-based chemotherapy as initial therapy for advanced or metastatic disease (stage IIIB or IV)
* First cycle of pembrolizumab received after 06/01/2018
* Permanently discontinued 1L pembrolizumab treatment
* Initiated second-line treatment at least 3 months prior to the date of data collection, with either :
* Afatinib
* Any chemotherapy
* Age ≥ 18 years
Exclusion Criteria:
-Received pembrolizumab in combination with platinum-based chemotherapy as part of an interventional clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04552535
Study Brief:
Protocol Section:
NCT04552535